Bioxytran, Inc. experienced a notable decline in short interest during December 2023, with figures dropping by 50.1% within the month. As of December 31, short interest totaled 7,224 shares, a significant reduction from 14,465 shares reported on December 15. This shift indicates changing investor sentiment towards the company. Based on an average daily trading volume of 386,938 shares, the short-interest ratio currently stands at 0.0 days, suggesting a minimal percentage of the stock is sold short.
Bioxytran’s stock performance reflects these changes. On Thursday, shares of OTCMKTS:BIXT opened at $0.06. The company has recorded a fifty-two week low of $0.04 and a high of $0.23. With a market capitalization of $6.49 million, Bioxytran has a price-to-earnings ratio of -2.00 and a beta of 2.15. Its 50-day and 200-day simple moving averages are $0.07 and $0.08, respectively.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical-stage biotechnology firm concentrating on the development of synthetic oxygen carriers and innovative oxygen therapeutics. These products target both acute care and chronic disease applications. The company’s proprietary platform is engineered to safely deliver therapeutic levels of oxygen to hypoxic tissues, which addresses critical conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injuries.
The company’s lead product candidates aim to meet significant medical needs in areas including cardiovascular and neurological disorders, wound healing, and critical care environments. Bioxytran’s research pipeline includes several preclinical-stage assets that utilize stabilized perfluorocarbon emulsions to facilitate controlled oxygen release.
As Bioxytran continues to advance its innovative therapies, the market will be keenly observing how these developments impact investor confidence and overall stock performance.
